Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.64 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.64 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6227077 | 0.90 | F10 (0.69) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL6592001 | 0.89 | F10 (0.81) | F10 | |
| SCHEMBL16554325 | 0.88 | F10 (0.74) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL6590511 | 0.84 | F10 (1.00) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL6591396 | 0.82 | F10 (1.00) | F10 | |
| SCHEMBL6594123 | 0.82 | F10 (0.89) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL14315172 | 0.82 | MAPT (1.00) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL6592241 | 0.81 | F10 (1.00) | F10SMN1; SMN2MAPTTP53RXFP1 | |
| SCHEMBL6593805 | 0.81 | F10 (1.00) | F10 | |
| SCHEMBL6594046 | 0.81 | F10 (0.82) | F10MAPTKMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| EP-2720695-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NoNO Inc. (CA) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | F10 2676/4885SMN1; SMN2 2627/4885MAPT 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.